Pharmacokinetic interaction between tandospirone and fluvoxamine in the rat contextual conditioned fear stress model and its functional consequence: Involvement of cytochrome P450 3A4

Psychiatry and Clinical Neurosciences

Volumn 62, Issue 5, 2008, Pages 591-596

  Nishikawa, Hiroyuki ^a   Inoue, Takeshi ^a   Masui, Takuya ^a   Izumi, Takeshi ^a   Nakagawa, Shin ^a   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Conditioned fear; Cytochrome P450 3A4; Drug interaction; Fluvoxamine; Tandospirone

Indexed keywords

CYTOCHROME P450 3A4; FLUVOXAMINE; TANDOSPIRONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENTIATION; FEAR; MALE; MOTOR ACTIVITY; NONHUMAN; RAT; SINGLE DRUG DOSE; TRANQUILIZING ACTIVITY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ANXIETY AGENTS; CONDITIONING, CLASSICAL; CYTOCHROME P-450 CYP3A; DRUG SYNERGISM; ELECTROSHOCK; FEAR; FLUVOXAMINE; ISOINDOLES; MALE; PIPERAZINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 53149130607     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2008.01853.x     Document Type: Article

References (23)

1. Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J. Clin. Psychiatry 1982 43 : 103 108.
2. Jacobson AF, Dominguez RA, Goldstein BJ, Steinbook RM. Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy 1985 5 : 290 296.
3. Feighner JP, Boyer WF. Serotonin-1A anxiolytics: An overview. Psychopathology 1989 22 (Suppl. 1 21 26.
4. Nishitsuji K, To H, Murakami Y et al. Tandospirone in the treatment of generalized anxiety disorder and mixed anxiety-depression. Clin. Drug Invest. 2004 24 : 121 126.
5. Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Ther. 1997 62 : 348 354.
6. Lamberg TS, Kivisto KT, Neuvonen PJ. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin. Pharmacol. Ther. 1998 63 : 640 645.
7. Niwa T, Shiraga T, Ishii I, Kagayama A, Takagi A. Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol. Pharm. Bull. 2005 28 : 1711 1716.
8. Natsui K, Mizuno Y, Tani N, Yabuki M, Komuro S. Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet. 2007 32 : 233 240.
9. Nishikawa H, Inoue T, Masui T, Izumi T, Koyama T. Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007 31 : 926 931.
10. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 1996 51 : 73 78.
11. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur. J. Clin. Pharmacol. 1994 46 : 35 39.
12. Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J. Clin. Pharmacol. 2003 43 : 1274 1282.
13. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J. Clin. Psychiatry 1993 54 : 269 271.
14. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J. Clin. Psychopharmacol. 1998 18 : 465 469.
15. Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukkarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: Results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J. Clin. Psychiatry 2001 62 : 448 452.
16. Anderson IM, Deakin JF, Miller HE. The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone in normal volunteers. Psychopharmacology (Berl) 1996 128 : 74 82.
17. Lamberg TS, Kivisto KT, Laitila J, Martensson K, Neuvonen PJ. The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone. Eur. J. Clin. Pharmacol. 1998 54 : 761 766.
18. Fanselow MS. Conditioned and unconditional components of post-shock freezing. Pavlov. J. Biol. Sci. 1980 15 : 177 182.
19. Ohmori T, Abekawa T, Muraki A, Koyama T. Competitive and noncompetitive NMDA antagonists block sensitization to methamphetamine. Pharmacol. Biochem. Behav. 1994 48 : 587 591.
20. Mochizuki D, Tsujita R, Yamada S et al. Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berl) 2002 162 : 323 332.
21. Abe M, Nakai H, Tabata R, Saito K, Egawa M. Effect of 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy]-1,3-benzodioxole HCl (MKC-242), a novel 5-HT1A-receptor agonist, on aggressive behavior and marble burying behavior in mice. Jpn. J. Pharmacol. 1998 76 : 297 304.
22. Nishikawa H, Inoue T, Izumi T, Koyama T. Synergistic effects of tandospirone and selective serotonin reuptake inhibitors on the contextual conditioned fear stress response in rats. Eur. Neuropsychopharmacol. 2007 17 : 643 650.
23. Goa KL, Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986 32 : 114 129.